2025-09-05 09:36:00
Click:
On September 4, a delegation of Taiwanese youth from the 'Fujian Hometown Camp' of the All-China Taiwanese Compatriots Association (ACTA) Youth Summer Camp visited LBE Pharma. The event aimed to deepen Taiwanese youth’s understanding of mainland China’s high-end pharmaceutical enterprises and industry development through on-site visits, foster in-depth exchanges between cross-Strait youth in pharmaceutical technology innovation, and jointly build a model for cross-Strait integrated development.

At the start of the event, Dr. Lu Yang, the company’s R&D Director, delivered a comprehensive and in-depth explanation of the technological breakthroughs and application value of the company’s emergency auto-injectors and dual-chamber prefilled syringes. Combining physical demonstrations with case studies, Dr. Lu illustrated LBE’s innovative strength in high-end pharmaceutical formulations from perspectives of product R&D logic, key technical barriers, and market application scenarios. The Taiwanese youth showed strong interest in the company’s innovative technologies and products, and engaged in active interactions with Dr. Lu to discuss technical details and R&D directions.

Later, under the guidance of Wan Lixiang, the Production Manager, the delegation visited LBE Pharma’s production lines. By observing the sophisticated manufacturing processes and rigorous quality control systems up close, the Taiwanese youth gained a more intuitive and profound understanding of the company’s R&D capabilities, manufacturing standards, and pursuit of excellence.


This visit not only allowed the Taiwanese youth to personally experience the vigorous vitality of the mainland economy and the strong momentum of LBE’s technological innovation, but also further narrowed the psychological distance between cross-Strait youth. The company will continue to play its role as a bridge for cross-Strait integration, promote the sharing of pharmaceutical industry resources between Fujian and Taiwan, and contribute to the development of the cross-Strait big health industry.

More information